{"pmid":32484942,"title":"Potential pitfalls of routine SARS-CoV-2 serology for mass screening.","text":["Potential pitfalls of routine SARS-CoV-2 serology for mass screening.","There are potential pitfalls of routine SARS-CoV-2 serology for mass screening. This article is protected by copyright. All rights reserved.","J Med Virol","Belec, Laurent","Pere, Helene","Bouassa, Ralph-Sydney Mboumba","Veyer, David","Jenabian, Mohammad-Ali","32484942"],"abstract":["There are potential pitfalls of routine SARS-CoV-2 serology for mass screening. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Belec, Laurent","Pere, Helene","Bouassa, Ralph-Sydney Mboumba","Veyer, David","Jenabian, Mohammad-Ali"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32484942","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26034","keywords":["covid-19","coronaviruses","mass screening","sars-cov-2","serology testing"],"topics":["Prevention","Diagnosis"],"weight":1,"_version_":1668532114718457856,"score":9.490897,"similar":[{"pmid":32459192,"title":"Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence.","text":["Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence.","The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from initial diagnosis to patient monitoring and treatment. Initial response to this pandemic involved the development, production, and distribution of diagnostic molecular assays at an unprecedented rate, leading to minimal validation requirements and concerns regarding their diagnostic accuracy in clinical settings. In addition to molecular testing, serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now becoming available from numerous diagnostic manufacturers. In both cases, the lack of peer-reviewed data and regulatory oversight, combined with general misconceptions regarding their appropriate use, have highlighted the importance of laboratory professionals in robustly validating and evaluating these assays for appropriate clinical use. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 has been established to synthesize up-to-date information on the epidemiology, pathogenesis, and laboratory diagnosis and monitoring of COVID-19, as well as to develop practical recommendations on the use of molecular, serological, and biochemical tests in disease diagnosis and management. This review summarizes the latest evidence and status of molecular, serological, and biochemical testing in COVID-19 and highlights some key considerations for clinical laboratories operating to support the global fight against this ongoing pandemic. Confidently this consolidated information provides a useful resource to laboratories and a reminder of the laboratory's critical role as the world battles this unprecedented crisis.","Clin Chem Lab Med","Bohn, Mary Kathryn","Lippi, Giuseppe","Horvath, Andrea","Sethi, Sunil","Koch, David","Ferrari, Maurizio","Wang, Cheng-Bin","Mancini, Nicasio","Steele, Shannon","Adeli, Khosrow","32459192"],"abstract":["The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from initial diagnosis to patient monitoring and treatment. Initial response to this pandemic involved the development, production, and distribution of diagnostic molecular assays at an unprecedented rate, leading to minimal validation requirements and concerns regarding their diagnostic accuracy in clinical settings. In addition to molecular testing, serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now becoming available from numerous diagnostic manufacturers. In both cases, the lack of peer-reviewed data and regulatory oversight, combined with general misconceptions regarding their appropriate use, have highlighted the importance of laboratory professionals in robustly validating and evaluating these assays for appropriate clinical use. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 has been established to synthesize up-to-date information on the epidemiology, pathogenesis, and laboratory diagnosis and monitoring of COVID-19, as well as to develop practical recommendations on the use of molecular, serological, and biochemical tests in disease diagnosis and management. This review summarizes the latest evidence and status of molecular, serological, and biochemical testing in COVID-19 and highlights some key considerations for clinical laboratories operating to support the global fight against this ongoing pandemic. Confidently this consolidated information provides a useful resource to laboratories and a reminder of the laboratory's critical role as the world battles this unprecedented crisis."],"journal":"Clin Chem Lab Med","authors":["Bohn, Mary Kathryn","Lippi, Giuseppe","Horvath, Andrea","Sethi, Sunil","Koch, David","Ferrari, Maurizio","Wang, Cheng-Bin","Mancini, Nicasio","Steele, Shannon","Adeli, Khosrow"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459192","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1515/cclm-2020-0722","keywords":["covid-19","sars-cov-2","biochemical monitoring","molecular testing","serology testing"],"topics":["Diagnosis"],"weight":1,"_version_":1667967698909265920,"score":112.83208},{"pmid":32306864,"title":"Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients.","text":["Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients.","Effective strategy to mitigate the ongoing pandemic of 2019 novel coronavirus (COVID-19) require a comprehensive understanding of humoral responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the emerging virus causing COVID-19. The dynamic profile of viral replication and shedding along with viral antigen specific antibody responses among COVID-19 patients started to be reported but there is no consensus on their patterns. Here, we conducted a serial investigation on 21 individuals infected with SARS-CoV-2 in two medical centres from Jiangsu Province, including 11 non-severe COVID-19 patients, and 5 severe COVID-19 patients and 5 asymptomatic carriers based on nucleic acid test and clinical symptoms. The longitudinal swab samples and sera were collected from these people for viral RNA testing and antibody responses, respectively. Our data revealed different pattern of seroconversion among these groups. All 11 non-severe COVID-19 patients and 5 severe COVID-19 patients were seroconverted during hospitalization or follow-up period, suggesting that serological testing is a complementary assay to nucleic acid test for those symptomatic COVID-19 patients. Of note, immediate antibody responses were identified among severe cases, compared to non-severe cases. On the other hand, only one were seroconverted for asymptomatic carriers. The SARS-CoV-2 specific antibody responses were well-maintained during the observation period. Such information is of immediate relevance and would assist COVID-19 clinical diagnosis, prognosis and vaccine design.","Emerg Microbes Infect","Yongchen, Zhang","Shen, Han","Wang, Xinning","Shi, Xudong","Li, Yang","Yan, Jiawei","Chen, Yuxin","Gu, Bing","32306864"],"abstract":["Effective strategy to mitigate the ongoing pandemic of 2019 novel coronavirus (COVID-19) require a comprehensive understanding of humoral responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the emerging virus causing COVID-19. The dynamic profile of viral replication and shedding along with viral antigen specific antibody responses among COVID-19 patients started to be reported but there is no consensus on their patterns. Here, we conducted a serial investigation on 21 individuals infected with SARS-CoV-2 in two medical centres from Jiangsu Province, including 11 non-severe COVID-19 patients, and 5 severe COVID-19 patients and 5 asymptomatic carriers based on nucleic acid test and clinical symptoms. The longitudinal swab samples and sera were collected from these people for viral RNA testing and antibody responses, respectively. Our data revealed different pattern of seroconversion among these groups. All 11 non-severe COVID-19 patients and 5 severe COVID-19 patients were seroconverted during hospitalization or follow-up period, suggesting that serological testing is a complementary assay to nucleic acid test for those symptomatic COVID-19 patients. Of note, immediate antibody responses were identified among severe cases, compared to non-severe cases. On the other hand, only one were seroconverted for asymptomatic carriers. The SARS-CoV-2 specific antibody responses were well-maintained during the observation period. Such information is of immediate relevance and would assist COVID-19 clinical diagnosis, prognosis and vaccine design."],"journal":"Emerg Microbes Infect","authors":["Yongchen, Zhang","Shen, Han","Wang, Xinning","Shi, Xudong","Li, Yang","Yan, Jiawei","Chen, Yuxin","Gu, Bing"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32306864","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1080/22221751.2020.1756699","keywords":["covid-19","sars-cov-2","antibody responses","serology testing","viral nucleic acid"],"locations":["Jiangsu","sera"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138491145158657,"score":104.708336},{"pmid":32311142,"title":"Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China.","text":["Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China.","The Wuhan City has ended the lockdown and people have been allowed to resume working since April 8 if meeting a set of COVID-19-associated tests including SARS-CoV-2 nucleic acid test (NAT) of nasopharyngeal swabs, chest CT scan or a SARS-CoV-2-specific serological test. Here, we reported the positive rate of COVID-19 tests based on NAT, chest CT scan and a serological SARS-CoV-2 test, from April 3 to 15 in one hospital in Qingshan Destrict, Wuhan. We observed a ~10% SARS-CoV-2-specific IgG positive rate from 1,402 tests. Combination of SARS-CoV-2 NAT and a specific serological test might facilitate the detection of COVID-19 infection, or the asymptomatic SARS-CoV-2-infected subjects. Large-scale investigation is required to evaluate the herd immunity of the city, for the resuming people and for the re-opened city. This article is protected by copyright. All rights reserved.","J Med Virol","Wu, Xiaodong","Fu, Bo","Chen, Lang","Feng, Yong","32311142"],"abstract":["The Wuhan City has ended the lockdown and people have been allowed to resume working since April 8 if meeting a set of COVID-19-associated tests including SARS-CoV-2 nucleic acid test (NAT) of nasopharyngeal swabs, chest CT scan or a SARS-CoV-2-specific serological test. Here, we reported the positive rate of COVID-19 tests based on NAT, chest CT scan and a serological SARS-CoV-2 test, from April 3 to 15 in one hospital in Qingshan Destrict, Wuhan. We observed a ~10% SARS-CoV-2-specific IgG positive rate from 1,402 tests. Combination of SARS-CoV-2 NAT and a specific serological test might facilitate the detection of COVID-19 infection, or the asymptomatic SARS-CoV-2-infected subjects. Large-scale investigation is required to evaluate the herd immunity of the city, for the resuming people and for the re-opened city. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Wu, Xiaodong","Fu, Bo","Chen, Lang","Feng, Yong"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311142","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25904","keywords":["coronavirus < virus classification","humoral immunity < immune responses","inapparent infection < epidemiology"],"locations":["Wuhan","Qingshan Destrict","Wuhan","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491155644416,"score":99.77182},{"pmid":32501021,"title":"Community-based screening and testing for Coronavirus in Cape Town, South Africa: Short report.","text":["Community-based screening and testing for Coronavirus in Cape Town, South Africa: Short report.","Corona Virus Infectious Disease 2019 (COVID-19) was first reported in Cape Town in March 2020 and the transmission was soon observed in local communities. Cape Town has many vulnerable communities because of poverty, overcrowding and comorbidities, although it has a relatively small elderly population. Amongst the unique and early responses to the pandemic in South Africa has been the strategy of community screening and testing (CST). This process has been drawn from health department's prior adoption of a community-orientated primary care (COPC) approach, which relies on teams of community health workers working in delineated communities to prevent disease and provide early interventions for those at higher risk. The COPC principles were applied in the CST programme, which involved collaboration between facility and community-based teams, linking public health and primary care approaches, careful mapping of cases in highly vulnerable communities, targeted screening around cases, testing of those that screened positive, health education and linkage to primary care. The overall aim was to slow down transmission through early identification and isolation of diagnosed cases. Key challenges involved the designing of a screening tool with appropriate sensitivity and specificity as well as the logistics of staffing, transport, consumables, data collection and capture, security, ablutions and personal protective equipment. Key opportunities included synergies between CST and evolving commitment to COPC in the health system. Key threats were the deteriorating security situation in the most vulnerable communities because of loss of income, food insecurity and CST distrust as well as increasing turn-around-times for test results.","Afr J Prim Health Care Fam Med","David, Neal","Mash, Robert","32501021"],"abstract":["Corona Virus Infectious Disease 2019 (COVID-19) was first reported in Cape Town in March 2020 and the transmission was soon observed in local communities. Cape Town has many vulnerable communities because of poverty, overcrowding and comorbidities, although it has a relatively small elderly population. Amongst the unique and early responses to the pandemic in South Africa has been the strategy of community screening and testing (CST). This process has been drawn from health department's prior adoption of a community-orientated primary care (COPC) approach, which relies on teams of community health workers working in delineated communities to prevent disease and provide early interventions for those at higher risk. The COPC principles were applied in the CST programme, which involved collaboration between facility and community-based teams, linking public health and primary care approaches, careful mapping of cases in highly vulnerable communities, targeted screening around cases, testing of those that screened positive, health education and linkage to primary care. The overall aim was to slow down transmission through early identification and isolation of diagnosed cases. Key challenges involved the designing of a screening tool with appropriate sensitivity and specificity as well as the logistics of staffing, transport, consumables, data collection and capture, security, ablutions and personal protective equipment. Key opportunities included synergies between CST and evolving commitment to COPC in the health system. Key threats were the deteriorating security situation in the most vulnerable communities because of loss of income, food insecurity and CST distrust as well as increasing turn-around-times for test results."],"journal":"Afr J Prim Health Care Fam Med","authors":["David, Neal","Mash, Robert"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501021","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.4102/phcfm.v12i1.2499","keywords":["covid-19","community health workers","community-orientated primary care","mass screening","primary care"],"locations":["Cape Town","South Africa","Cape Town","South Africa"],"countries":["South Africa"],"countries_codes":["ZAF|South Africa"],"topics":["Prevention"],"weight":1,"_version_":1668804508923199488,"score":93.280785},{"pmid":32383171,"title":"Asymptomatic Cases with SARS-CoV-2 Infection.","text":["Asymptomatic Cases with SARS-CoV-2 Infection.","On March 31, 2020, Chinese Health Authorization announced that numbers of asymptomatic cases with SARS-CoV-2 infection will be made to public daily. This was a very important step since different counties have different capacity for detection of SARS-CoV-2 infection and control strategy for COVID-19 outbreak. We summarized the characteristics of asymptomatic SARS-CoV-2 infections and the transmission potential of asymptomatic cases. Then we provided guidelines fo_r the management of asymptomatic cases through quarantine and nucleic acid/serology tests. This article is protected by copyright. All rights reserved.","J Med Virol","Wang, Yishan","Kang, Hanyujie","Liu, Xuefeng","Tong, Zhaohui","32383171"],"abstract":["On March 31, 2020, Chinese Health Authorization announced that numbers of asymptomatic cases with SARS-CoV-2 infection will be made to public daily. This was a very important step since different counties have different capacity for detection of SARS-CoV-2 infection and control strategy for COVID-19 outbreak. We summarized the characteristics of asymptomatic SARS-CoV-2 infections and the transmission potential of asymptomatic cases. Then we provided guidelines fo_r the management of asymptomatic cases through quarantine and nucleic acid/serology tests. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Wang, Yishan","Kang, Hanyujie","Liu, Xuefeng","Tong, Zhaohui"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383171","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25990","keywords":["coronavirus < virus classification","horizontal transmission < epidemiology","respiratory tract < pathogenesis","sars coronavirus < virus classification"],"topics":["Transmission","Diagnosis","Treatment","Prevention"],"weight":1,"_version_":1666267276738822144,"score":88.56283}]}